General Dermatology

Emerging skin treatments present unique clinical challenges that must be anticipated by clinicians.

Recent FDA approvals for topical roflumilast and ruxolitinib down to age 2 mark major milestones in managing pediatric AD, according to Peter Lio, MD.

Del Rosso recounts the meeting’s evolution and its consistent mission to bridge science and practice.

Click through this slideshow to see what faces familiar to Dermatology Times will be on the speaker stand at Fall Clinical this week.

Peter Lio, MD, describes Fall Clinical as an energizing, high-level dermatology meeting focused on practical takeaways and collaboration.

Surface keratin 1 has emerged as a promising target in triple-negative breast cancer, bridging dermatology and oncology for innovative treatments.

Fall Clinical 2025 continues its tradition of blending cutting-edge science with practical insights for the modern dermatologist.

New evidence supports biologic agents as precise, better-tolerated alternatives to systemic immunosuppressants for life-threatening dermatologic emergencies.

This October, discover how dermatology and oncology collaborate to enhance breast cancer care and support patients through innovative therapies and teamwork.

Explore the intricate link between dermatology and psychiatric disorders, revealing how mental health impacts skin conditions and treatment approaches.

Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the approval of cemiplimab as adjuvant immunotherapy for high-risk CSCC, FDA safety communication on RF microneedling, dermatologists' role in breast cancer awareness, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore essential insights on breast cancer diagnosis and dermatology, highlighting key practices for early detection and patient care.

Explore the critical role of dermatologists in managing cutaneous toxicities from breast cancer therapies, enhancing patient quality of life and treatment outcomes.

Researchers found that while 96% of respondents use social media daily, most dermatologic information encountered online remains inaccurate or non-evidence-based.

Topical dapsone shows promise in treating various mucocutaneous diseases, including rosacea and neutrophilic dermatoses, with a favorable safety profile.

Yale researchers uncover how skin stem cells enhance healing during embryonic development, paving the way for advanced skin grafts and regenerative medicine.

Dermatologists play a vital role in identifying breast cancer symptoms, bridging gaps in care for conditions like Paget disease and inflammatory breast cancer.

If passed, the Safe Step Act could reduce treatment delays by prohibiting step therapy for FDA-labeled, guideline-supported agents.

Dermatologists enhance breast cancer care by managing skin issues, identifying genetic risks, and improving patient quality of life during treatment.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about roflumilast's expanded access for children as young as 2, LP-10 for oral lichen planus, SYX-5219's IND clearance, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.